Xingrong Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xingrong Song has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Ziwen Shi
Department of Anesthesiology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University,Guangzhou, China
7 shared publicationsJingwen Qin
Department of Anesthesiology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, People’s Republic of China
6 shared publicationsNa Zhang
Department of Anesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510632, P.R. China
6 shared publicationsWei Wei
Department of Anesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, China
5 shared publicationsTianyun Zhao
Department of Anesthesiology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, People’s Republic of China
4 shared publicationsXinying Guo
Department of Anesthesiology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University,Guangzhou, China
4 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 24 (4) , 494-512
Therapeutic Values of General Anesthetics: From Developmental Neurotoxicity to Neurotherapeutic Agents
The development of the central nervous system is characterized by precisely orchestrated, dynamic processes that commence at the embryonic stage and continue throughout postnatal life. Maintaining the balance between excitation/inhibition (E/I) in cortical neuronal circuits is crucial for normal brain function. General anesthetics (GAs) powerfully modulate neuronal activity by enhancing inhibition and/or inhibiting excitability, resulting in temporary loss of consciousness. Therefore, these agents can also induce aberrant neuroplasticity contributing to neurological dysfunction and abnormal behavioural phenotypes, particularly in the developing brain. While this impaired plasticity poses a risk, it also creates an opportunity to treat diseases characterised by abnormal neuroplasticity as core pathologies, such as neuropsychiatric disorders (NPDs). Over recent decades, intense investigations have revealed the neuroprotective and psychotherapeutic potential of GAs in treating neurological injuries and NPDs. Although promising, significant challenges remain, including optimizing dosages, administration duration, and intervals for non-anesthetic uses while minimizing adverse effects. Additionally, the molecular mechanisms underlying the dual roles of GAs - as neurotoxic agents and neurotherapeutic tools - require further elucidation. This review explores developmental neuroplasticity during critical periods, the mechanisms of GAs' action on neural circuits, and the current understanding of their neurotoxic and neuroprotective effects based on alterations in neuroplasticity. Furthermore, we highlight the therapeutic potential of GAs for neurological disorders with impaired neuroplasticity as the core pathological mechanism and propose directions for future research to unlock their full clinical utility.
- 1 April 2026
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 24 (4) , 494-512
Open AccessTherapeutic Values of General Anesthetics: From Developmental Neurotoxicity to Neurotherapeutic Agents
The development of the central nervous system is characterized by precisely orchestrated, dynamic processes that commence at the embryonic stage and continue throughout postnatal life. Maintaining the balance between excitation/inhibition (E/I) in cortical neuronal circuits is crucial for normal brain function. General anesthetics (GAs) powerfully modulate neuronal activity by enhancing inhibition and/or inhibiting excitability, resulting in temporary loss of consciousness. Therefore, these agents can also induce aberrant neuroplasticity contributing to neurological dysfunction and abnormal behavioural phenotypes, particularly in the developing brain. While this impaired plasticity poses a risk, it also creates an opportunity to treat diseases characterised by abnormal neuroplasticity as core pathologies, such as neuropsychiatric disorders (NPDs). Over recent decades, intense investigations have revealed the neuroprotective and psychotherapeutic potential of GAs in treating neurological injuries and NPDs. Although promising, significant challenges remain, including optimizing dosages, administration duration, and intervals for non-anesthetic uses while minimizing adverse effects. Additionally, the molecular mechanisms underlying the dual roles of GAs - as neurotoxic agents and neurotherapeutic tools - require further elucidation. This review explores developmental neuroplasticity during critical periods, the mechanisms of GAs' action on neural circuits, and the current understanding of their neurotoxic and neuroprotective effects based on alterations in neuroplasticity. Furthermore, we highlight the therapeutic potential of GAs for neurological disorders with impaired neuroplasticity as the core pathological mechanism and propose directions for future research to unlock their full clinical utility.
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-17
Low-Dose Sevoflurane Restores Prefrontal Excitatory/Inhibitory Balance and Improves Autism-Like Social Behavior: A Preclinical and Pilot Clinical Study
Background: Medications aimed at modulating excitatory/inhibitory (E/I) balance have shown promise in alleviating the behavioral manifestations of autism spectrum disorder (ASD). We therefore aimed to investigate the potential of low-concentration sevoflurane, a GABAA agonist, to modulate E/I balance and affect autism-like behavior deficit in BTBR mice and ASD patients. Methods: In the preclinical study, BTBR mice were exposed to 1% sevoflurane for 30 minutes daily, 5 days per week, from postnatal weeks 4 to 6. Behavioral and electrophysiological assessments were performed. In the clinical trial, ASD patients received 1% sevoflurane treatments for 2 hours per session, 3– 5 times during the first two weeks, followed by 2– 3 sessions per week for a total of 12 weeks. Assessments were conducted at baseline and the 14th week. The primary outcomes were evaluated using the Childhood Autism Rating Scale (CARS) and Clinical Global Impressions-Improvement (CGI-I) scale, while secondary outcomes were assessed using the Autism Diagnostic Observation Schedule-2 (ADOS-2), Clinical Global Impression-Severity Scale (CGI-S), Autism Treatment Evaluation Checklist (ATEC), and Autism Behavior Checklist (ABC). Results: Our preclinical results demonstrated that repeated exposure to low-concentration sevoflurane restored E/I balance and improved social interaction and social memory without affecting repetitive behaviors. Accordingly, an open-label and single-arm clinical trial enrolled 20 ASD patients in Guangzhou Women and Children’s Medical Center. Significant reduction in CARS score of 4.7 points was observed between baseline and the end of treatment, which is both statistically and clinically significant. Additionally, 61% of ASD children demonstrated a positive response as measured by the CGI-I scale. Furthermore, analysis of secondary outcomes revealed that sevoflurane treatment primarily improved social impairments in ASD patients. Importantly, no significant safety concerns were observed during the one-year follow-up. Conclusion: Low-concentration sevoflurane shows promise as a novel therapeutic strategy for improving social deficits in ASD by modulating E/I balance. Trial Registration: Chinese Clinical trial Number: ChiCTR1900027459.
- 1 February 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-17
Open AccessLow-Dose Sevoflurane Restores Prefrontal Excitatory/Inhibitory Balance and Improves Autism-Like Social Behavior: A Preclinical and Pilot Clinical Study
Background: Medications aimed at modulating excitatory/inhibitory (E/I) balance have shown promise in alleviating the behavioral manifestations of autism spectrum disorder (ASD). We therefore aimed to investigate the potential of low-concentration sevoflurane, a GABAA agonist, to modulate E/I balance and affect autism-like behavior deficit in BTBR mice and ASD patients. Methods: In the preclinical study, BTBR mice were exposed to 1% sevoflurane for 30 minutes daily, 5 days per week, from postnatal weeks 4 to 6. Behavioral and electrophysiological assessments were performed. In the clinical trial, ASD patients received 1% sevoflurane treatments for 2 hours per session, 3– 5 times during the first two weeks, followed by 2– 3 sessions per week for a total of 12 weeks. Assessments were conducted at baseline and the 14th week. The primary outcomes were evaluated using the Childhood Autism Rating Scale (CARS) and Clinical Global Impressions-Improvement (CGI-I) scale, while secondary outcomes were assessed using the Autism Diagnostic Observation Schedule-2 (ADOS-2), Clinical Global Impression-Severity Scale (CGI-S), Autism Treatment Evaluation Checklist (ATEC), and Autism Behavior Checklist (ABC). Results: Our preclinical results demonstrated that repeated exposure to low-concentration sevoflurane restored E/I balance and improved social interaction and social memory without affecting repetitive behaviors. Accordingly, an open-label and single-arm clinical trial enrolled 20 ASD patients in Guangzhou Women and Children’s Medical Center. Significant reduction in CARS score of 4.7 points was observed between baseline and the end of treatment, which is both statistically and clinically significant. Additionally, 61% of ASD children demonstrated a positive response as measured by the CGI-I scale. Furthermore, analysis of secondary outcomes revealed that sevoflurane treatment primarily improved social impairments in ASD patients. Importantly, no significant safety concerns were observed during the one-year follow-up. Conclusion: Low-concentration sevoflurane shows promise as a novel therapeutic strategy for improving social deficits in ASD by modulating E/I balance. Trial Registration: Chinese Clinical trial Number: ChiCTR1900027459.
- Open Access
- 22 December 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 33 (2) , 1-12
Melatonin induces autophagy in neuroblastoma by alleviating Pak2‑mediated endoplasmic reticulum stress
Neuroblastoma (NB), the most common extracranial solid tumor in children, remains challenging to treat due to limited therapeutic efficacy and poor prognosis. Emerging evidence highlights the critical roles of endoplasmic reticulum (ER) stress and autophagy in cancer progression. The present study investigated the therapeutic potential of melatonin in neuroblastoma and its underlying mechanisms. Using Neuro‑2a (N2a) cells, it demonstrated that melatonin alleviated ER stress by upregulating ER chaperones glucose‑regulated protein (GRP)78 and GRP94 and the pro‑apoptotic protein CHOP, while enhancing autophagic activity. Western blotting revealed increased LC3‑II/I ratios, elevated autophagy‑related protein 5 and Beclin1 levels, and reduced p62 expression, indicating autophagy induction. Immunofluorescence and transmission electron microscopy confirmed the dose‑dependent accumulation of autophagosomes. ER stress inhibitor 4‑phenylbutyric acid attenuated melatonin‑induced autophagy, linking ER stress relief to autophagic activation. Mechanistically, melatonin upregulated p21‑activated kinase 2 (Pak2), which suppressed mTOR phosphorylation and activated unc‑51‑like kinase 1, thereby modulating the AMP‑activated protein kinase (AMPK) pathway. Pak2 overexpression amplified melatonin's ER stress‑alleviating effects, whereas Pak2 knockdown or AMPK inhibition diminished its efficacy. These findings established that melatonin suppresses neuroblastoma growth by mitigating Pak2‑mediated ER stress to induce cytotoxic autophagy. The present study provided novel insights into melatonin as a promising therapeutic agent for neuroblastoma, warranting further exploration in preclinical models and clinical trials.
- 22 December 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 33 (2) , 1-12
Open AccessMelatonin induces autophagy in neuroblastoma by alleviating Pak2‑mediated endoplasmic reticulum stress
Neuroblastoma (NB), the most common extracranial solid tumor in children, remains challenging to treat due to limited therapeutic efficacy and poor prognosis. Emerging evidence highlights the critical roles of endoplasmic reticulum (ER) stress and autophagy in cancer progression. The present study investigated the therapeutic potential of melatonin in neuroblastoma and its underlying mechanisms. Using Neuro‑2a (N2a) cells, it demonstrated that melatonin alleviated ER stress by upregulating ER chaperones glucose‑regulated protein (GRP)78 and GRP94 and the pro‑apoptotic protein CHOP, while enhancing autophagic activity. Western blotting revealed increased LC3‑II/I ratios, elevated autophagy‑related protein 5 and Beclin1 levels, and reduced p62 expression, indicating autophagy induction. Immunofluorescence and transmission electron microscopy confirmed the dose‑dependent accumulation of autophagosomes. ER stress inhibitor 4‑phenylbutyric acid attenuated melatonin‑induced autophagy, linking ER stress relief to autophagic activation. Mechanistically, melatonin upregulated p21‑activated kinase 2 (Pak2), which suppressed mTOR phosphorylation and activated unc‑51‑like kinase 1, thereby modulating the AMP‑activated protein kinase (AMPK) pathway. Pak2 overexpression amplified melatonin's ER stress‑alleviating effects, whereas Pak2 knockdown or AMPK inhibition diminished its efficacy. These findings established that melatonin suppresses neuroblastoma growth by mitigating Pak2‑mediated ER stress to induce cytotoxic autophagy. The present study provided novel insights into melatonin as a promising therapeutic agent for neuroblastoma, warranting further exploration in preclinical models and clinical trials.
- 23 October 2025
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 131, 106148
Microglia-mediated Perineuronal nets loss contributes to social memory deficit in male mice after repeated neonatal sevoflurane exposure
- 23 October 2025
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 131, 106148
Microglia-mediated Perineuronal nets loss contributes to social memory deficit in male mice after repeated neonatal sevoflurane exposure
- 8 September 2025
- Published by Wiley in Pediatric Anesthesia
- Vol. 35 (11) , 913-924
Propofol Versus Sevoflurane Anesthesia for Acute Postoperative Pain Management in Pediatric Adenotonsillectomy: A Randomized Controlled Trial
Background: Pain following pediatric adenotonsillectomy is prevalent, frequently severe, and often inadequately managed. The effectiveness of propofol or sevoflurane anesthesia in acute postoperative pain management is unknown.Methods: We conducted a single‐blind, randomized controlled trial to examine the postoperative analgesic effectiveness of propofol or sevoflurane anesthesia. 144 children aged 2–7 years were enrolled and randomly assigned to receive either propofol or sevoflurane anesthesia, with 142 completing the study. The primary outcome was the proportion of acute postoperative pain measured by the Face, Legs, Activity, Cry, and Consolability (FLACC) scale scores > 3 within 24 h between the two groups. Secondary outcomes included postoperative pain assessed by the parent's postoperative pain measure (PPPM) scale and numeric rating scale (NRS) on the 1, 2, 3, 7, and 14 postoperative days, as well as perioperative adverse events.Results: The incidence of acute pain FLACC > 3 within 24 h showed comparable results between both groups (30 of 71 [42.3%] vs. 34 of 71 [47.9%]; odds ratio [OR] = 0.78, 95% confidence interval [CI]: [0.28, 2.18]; p = 0.500). The propofol group demonstrated higher pain scores on postoperative days 2–3, with between‐group median differences (ΔNRS at activity = 1, ΔPPPM = 1) below minimal clinically important difference thresholds (ΔNRS > 1, ΔPPPM > 3).Conclusions: The incidence and intensity of acute postoperative pain in the first 24 h after adenotonsillectomy did not differ significantly between pediatric patients who received maintenance anesthesia with propofol or with sevoflurane. The two general anesthesia techniques exhibited comparable clinical efficacy with respect to pain prognosis within 2 weeks.Trial Registration: The Chinese Clinical Trial Registry (ChiCTR2300075847, Date of registration: September 3, 2023)
- 8 September 2025
- Published by Wiley in Pediatric Anesthesia
- Vol. 35 (11) , 913-924
Propofol Versus Sevoflurane Anesthesia for Acute Postoperative Pain Management in Pediatric Adenotonsillectomy: A Randomized Controlled Trial
Background: Pain following pediatric adenotonsillectomy is prevalent, frequently severe, and often inadequately managed. The effectiveness of propofol or sevoflurane anesthesia in acute postoperative pain management is unknown.Methods: We conducted a single‐blind, randomized controlled trial to examine the postoperative analgesic effectiveness of propofol or sevoflurane anesthesia. 144 children aged 2–7 years were enrolled and randomly assigned to receive either propofol or sevoflurane anesthesia, with 142 completing the study. The primary outcome was the proportion of acute postoperative pain measured by the Face, Legs, Activity, Cry, and Consolability (FLACC) scale scores > 3 within 24 h between the two groups. Secondary outcomes included postoperative pain assessed by the parent's postoperative pain measure (PPPM) scale and numeric rating scale (NRS) on the 1, 2, 3, 7, and 14 postoperative days, as well as perioperative adverse events.Results: The incidence of acute pain FLACC > 3 within 24 h showed comparable results between both groups (30 of 71 [42.3%] vs. 34 of 71 [47.9%]; odds ratio [OR] = 0.78, 95% confidence interval [CI]: [0.28, 2.18]; p = 0.500). The propofol group demonstrated higher pain scores on postoperative days 2–3, with between‐group median differences (ΔNRS at activity = 1, ΔPPPM = 1) below minimal clinically important difference thresholds (ΔNRS > 1, ΔPPPM > 3).Conclusions: The incidence and intensity of acute postoperative pain in the first 24 h after adenotonsillectomy did not differ significantly between pediatric patients who received maintenance anesthesia with propofol or with sevoflurane. The two general anesthesia techniques exhibited comparable clinical efficacy with respect to pain prognosis within 2 weeks.Trial Registration: The Chinese Clinical Trial Registry (ChiCTR2300075847, Date of registration: September 3, 2023)
- Open Access
Effects of perioperative massive transfusion on postoperative outcomes of children undergoing brain tumor removal: a retrospective cohort study
Objective: To examine the influence of massive perioperative transfusion on both short-term and long-term outcomes in children undergoing brain tumor resection. Methods: This retrospective cohort study analyzed pediatric patients who underwent brain tumor surgeries at the Women and Children’s Medical Center, Guangzhou Medical University, between October 2014 and March 2022. Massive transfusion was characterized as the transfusion of red blood cells equivalent to or exceeding the estimated preoperative blood volume within 48 h after surgery. To evaluate the relationship between massive transfusion and patient outcomes, logistic regression models were utilized. Survival curves were constructed to compare the long-term outcomes of patients who received massive transfusion with those who did not. The primary outcomes assessed were 30-day all-cause mortality (short-term outcomes) and 1-year survival rates (short-term outcomes). Results: Among the 306 patients included in the analysis, 78 were categorized as part of the massive transfusion group, while 228 were in the non-massive transfusion group. Multivariable regression analysis indicated that perioperative massive transfusion was significantly linked to an increased risk of 30-day mortality (odds ratio (OR): 0.137, 95% confidence interval (CI) [0.036–0.528], p = 0.004). Additionally, patients in the massive transfusion group exhibited higher incidences of postoperative intracranial hypertension (OR: 4.788, 95% CI [1.547–14.824], p = 0.007), extended mechanical ventilation duration (OR: 0.247, 95% CI [58.739–147.895], p < 0.001), and prolonged intensive care unit (ICU) stays (ß = 0.184, 95% CI [3.874–15.077], p = 0.001). Conclusions: Massive transfusion has a pronounced impact on short-term outcomes, particularly increasing perioperative mortality and complication risks in children undergoing brain tumor surgery. Careful consideration of the risks and benefits of transfusion is crucial in managing these cases.
Open AccessEffects of perioperative massive transfusion on postoperative outcomes of children undergoing brain tumor removal: a retrospective cohort study
Objective: To examine the influence of massive perioperative transfusion on both short-term and long-term outcomes in children undergoing brain tumor resection. Methods: This retrospective cohort study analyzed pediatric patients who underwent brain tumor surgeries at the Women and Children’s Medical Center, Guangzhou Medical University, between October 2014 and March 2022. Massive transfusion was characterized as the transfusion of red blood cells equivalent to or exceeding the estimated preoperative blood volume within 48 h after surgery. To evaluate the relationship between massive transfusion and patient outcomes, logistic regression models were utilized. Survival curves were constructed to compare the long-term outcomes of patients who received massive transfusion with those who did not. The primary outcomes assessed were 30-day all-cause mortality (short-term outcomes) and 1-year survival rates (short-term outcomes). Results: Among the 306 patients included in the analysis, 78 were categorized as part of the massive transfusion group, while 228 were in the non-massive transfusion group. Multivariable regression analysis indicated that perioperative massive transfusion was significantly linked to an increased risk of 30-day mortality (odds ratio (OR): 0.137, 95% confidence interval (CI) [0.036–0.528], p = 0.004). Additionally, patients in the massive transfusion group exhibited higher incidences of postoperative intracranial hypertension (OR: 4.788, 95% CI [1.547–14.824], p = 0.007), extended mechanical ventilation duration (OR: 0.247, 95% CI [58.739–147.895], p < 0.001), and prolonged intensive care unit (ICU) stays (ß = 0.184, 95% CI [3.874–15.077], p = 0.001). Conclusions: Massive transfusion has a pronounced impact on short-term outcomes, particularly increasing perioperative mortality and complication risks in children undergoing brain tumor surgery. Careful consideration of the risks and benefits of transfusion is crucial in managing these cases.
- Open Access
- 2 July 2024
- Published by Elsevier in Neurotherapeutics
- Vol. 21 (5) , e00383
Fibroblast growth factor 3 contributes to neuropathic pain through Akt/mTOR signaling in mouse primary sensory neurons
- 2 July 2024
- Published by Elsevier in Neurotherapeutics
- Vol. 21 (5) , e00383
Open AccessFibroblast growth factor 3 contributes to neuropathic pain through Akt/mTOR signaling in mouse primary sensory neurons
- 22 May 2024
- Published by Wiley in Pediatric Anesthesia
- Vol. 34 (8) , 773-782
Reducing postoperative hypothermia in infants: Quality improvement in China
Background: Unintended postoperative hypothermia in infants is associated with increased mortality and morbidity. We noted consistent hypothermia postoperatively in more than 60% of our neonatal intensive care (NICU) babies. Therefore, we set out to determine whether a targeted quality improvement (QI) project could decrease postoperative hypothermia rates in infants.Objectives: Our SMART aim was to reduce postoperative hypothermia (37.5°C). Data collected was analyzed using control charts. The factors associated with a reduction in hypothermia were explored using regression analysis.Results: There were 295 infants in the project. The percentage of postoperative hypothermia decreased from 60% to 37% over 26 weeks, a special cause variation below the mean on the statistical process control chart. Reduction in hypothermia was associated with an odds of 0.17 (95% CI: 0.06–0.46; p <.001) for compliance with the transport incubator and 0.24 (95% CI: 0.1–0.58; p =.002) for prewarming the OR ambient temperature to 26°C. Two infants had hyperthermia.Conclusions: Our QI project reduced postoperative hypothermia without incurring hyperthermia through multidisciplinary team collaboration with the guidance of QI experts from the USA.
- 22 May 2024
- Published by Wiley in Pediatric Anesthesia
- Vol. 34 (8) , 773-782
Reducing postoperative hypothermia in infants: Quality improvement in China
Background: Unintended postoperative hypothermia in infants is associated with increased mortality and morbidity. We noted consistent hypothermia postoperatively in more than 60% of our neonatal intensive care (NICU) babies. Therefore, we set out to determine whether a targeted quality improvement (QI) project could decrease postoperative hypothermia rates in infants.Objectives: Our SMART aim was to reduce postoperative hypothermia (37.5°C). Data collected was analyzed using control charts. The factors associated with a reduction in hypothermia were explored using regression analysis.Results: There were 295 infants in the project. The percentage of postoperative hypothermia decreased from 60% to 37% over 26 weeks, a special cause variation below the mean on the statistical process control chart. Reduction in hypothermia was associated with an odds of 0.17 (95% CI: 0.06–0.46; p <.001) for compliance with the transport incubator and 0.24 (95% CI: 0.1–0.58; p =.002) for prewarming the OR ambient temperature to 26°C. Two infants had hyperthermia.Conclusions: Our QI project reduced postoperative hypothermia without incurring hyperthermia through multidisciplinary team collaboration with the guidance of QI experts from the USA.
- 12 May 2024
- Published by Wiley in Pediatric Anesthesia
- Vol. 34 (9) , 941-949
Pediatric anesthesia in China
In China, healthcare has lagged relative to its economic boom during the past 40 years. While the top tier hospitals offer pediatric perioperative care like high‐income countries, lower‐tier hospitals deliver lesser services of variable quality and safety related to equipment, supplies, clinician education, and availability. The national residency training program and the pediatric anesthesia fellowship program was established in 2013 and 2018 respectively. Increasing clinician workload from patient demand and a lack of consistency in quality and capability between rural and urban areas remain challenging.
- 12 May 2024
- Published by Wiley in Pediatric Anesthesia
- Vol. 34 (9) , 941-949
Pediatric anesthesia in China
In China, healthcare has lagged relative to its economic boom during the past 40 years. While the top tier hospitals offer pediatric perioperative care like high‐income countries, lower‐tier hospitals deliver lesser services of variable quality and safety related to equipment, supplies, clinician education, and availability. The national residency training program and the pediatric anesthesia fellowship program was established in 2013 and 2018 respectively. Increasing clinician workload from patient demand and a lack of consistency in quality and capability between rural and urban areas remain challenging.
- Open Access
- 28 October 2023
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 91 (5) , 516
A Composite Gene Polymorphism Signature for Preoperative Dexmedetomidine Sedation in Pediatrics: A Prospective Observational Study
- 28 October 2023
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 91 (5) , 516
Open AccessA Composite Gene Polymorphism Signature for Preoperative Dexmedetomidine Sedation in Pediatrics: A Prospective Observational Study